Merck Prices EUR 1.0 Billion Debt Offering
October 26 2016 - 1:31PM
Business Wire
Merck & Co., Inc., (NYSE:MRK), known as MSD outside the
United States and Canada, priced today a EUR 1.0 billion public
offering of two series of Euro-denominated senior unsecured notes
(collectively, the “New Notes”). Based on Oct. 21, 2016, closing
exchange rates the EUR 1.0 billion equates to approximately $1.087
billion. The notes include:
EUR 500 million of 0.500% notes due Nov.
2024EUR 500 million of 1.375% notes due Nov. 2036
Merck intends to use the net proceeds from the offering for
general corporate purposes, including without limitation repayment
of outstanding commercial paper borrowings and other indebtedness
with upcoming maturities. The offering is expected to close on Nov.
2, 2016, subject to customary closing conditions. BNP Paribas,
Citigroup Global Markets Limited, and Merrill Lynch International
are acting as the active joint book-running managers for the
offering.
The offering of the New Notes is being made pursuant to an
effective shelf registration statement (including a base
prospectus) filed with the Securities and Exchange Commission
(SEC). The offering may be made only by means of a prospectus and
related prospectus supplement, copies of which may be obtained by
calling BNP Paribas at (800) 854-5674, Citigroup Global Markets
Limited at (800) 831-9146, or Merrill Lynch International at (800)
294-1322. An electronic copy of the registration statement and
prospectus supplement, together with the base prospectus, is
available on the SEC’s website at www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction.
About Merck
For 125 years, Merck has been a global health care leader
working to help the world be well. Merck is known as MSD outside
the United States and Canada. Through our prescription medicines,
vaccines, biologic therapies and animal health products, we work
with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies,
programs and partnerships.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Such statements may
include, but are not limited to, the company’s ability to complete
the offering and the company’s expectations for the use of proceeds
from the offering. These statements are based upon the current
beliefs and expectations of the company’s management and are
subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2015
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161026006526/en/
Merck & Co., Inc.Media:Lainie Keller, 908-236-5036Tracy
Ogden, 267-305-2301orInvestors:Teri Loxam, 908-740-1986Amy Klug,
908-740-1898
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024